Spots Global Cancer Trial Database for neoplasm malignant
Every month we try and update this database with for neoplasm malignant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy | NCT04524728 | Breast Neoplasm Malign... Female | Palbociclib Letrozole 2.5mg Fulvestrant | 18 Years - | Istituti Clinici Scientifici Maugeri SpA | |
| A Study of PSB205 in Subjects With Advanced Solid Tumors | NCT03986606 | Neoplasm Malign... | PSB205 | 18 Years - | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | NCT01587040 | Neoplasm Malign... | SAR245408 SAR245409 | - | Sanofi | |
| Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients | NCT03873064 | Neoplasm Malign... Body Weight Quality of Life | 18 Years - | University of Rome Tor Vergata | ||
| Effect of SAR302503 on ECG Activity in Patients With Solid Tumors | NCT01836705 | Neoplasm Malign... | SAR302503 (TG10... Placebo SAR3025... Panolosetron | 18 Years - | Sanofi | |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | NCT05013554 | Neoplasm Malign... Breast Cancer Lung Neoplasm M... Gastric Cancer Neoplasm | SAR443216 IV SAR443216 SC | 18 Years - | Sanofi | |
| Evaluation of End of Life Quality of Care | NCT03775304 | Neoplasm Malign... Quality of Life End of Life Car... | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance | NCT06332001 | Neoplasm Malign... | Experimental Gr... Control Group | - | European Institute of Oncology | |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | NCT01527929 | Neoplasm Malign... | Cabazitaxel XRP... | 18 Years - | Sanofi | |
| First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor | NCT01156870 | Neoplasm Malign... | SAR566658 | 18 Years - | Sanofi | |
| An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | NCT01121588 | Neoplasms Malig... | Crizotinib | 15 Years - | Pfizer | |
| iKnife REIMS Project | NCT04067388 | Neoplasms Neoplasm Malign... | Rapid Evaporati... | 18 Years - | Imperial College London | |
| Evaluation of SAR408701 in Patients With Advanced Solid Tumors | NCT02187848 | Neoplasm Malign... | SAR408701 | 18 Years - | Sanofi | |
| Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | NCT03324113 | Neoplasm Malign... | SAR408701 dexamethasone naphazoline diphenhydramine | 20 Years - | Sanofi | |
| A Study of PSB205 in Subjects With Advanced Solid Tumors | NCT03986606 | Neoplasm Malign... | PSB205 | 18 Years - | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | |
| A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | NCT01596270 | Neoplasm Malign... | SAR245409 | 18 Years - | Sanofi | |
| Evaluation of End of Life Quality of Care | NCT03775304 | Neoplasm Malign... Quality of Life End of Life Car... | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas | NCT05850377 | High Grade Glio... Glioma Glioma, Maligna... Neoplasms, Neur... Neuroectodermal... Photosensitizin... Neoplasm Malign... Brain Neoplasms... Central Nervous... Brain Tumor Tumour, Residua... | 5-Aminolevulini... Fluorescence-Gu... | 18 Years - 75 Years | Sociedad de Lucha Contra el Cáncer del Ecuador | |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | NCT01527929 | Neoplasm Malign... | Cabazitaxel XRP... | 18 Years - | Sanofi | |
| Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment | NCT01140607 | Neoplasm Malign... | Cabazitaxel (XR... | 18 Years - 60 Years | Sanofi | |
| "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. | NCT05818865 | Neoplasm Malign... | CLG | 18 Years - | National Cancer Institute, Naples | |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | NCT04726332 | Neoplasm Malign... Epithelial Ovar... Triple Negative... Hormone Recepto... Metastatic Cast... | XL102 Fulvestrant Abiraterone Prednisone | 18 Years - | Exelixis | |
| A Study of SAR428926 in Patients With Advanced Solid Tumors | NCT02575781 | Neoplasm Malign... | SAR428926 | 18 Years - | Sanofi | |
| First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor | NCT01156870 | Neoplasm Malign... | SAR566658 | 18 Years - | Sanofi | |
| A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | NCT01596270 | Neoplasm Malign... | SAR245409 | 18 Years - | Sanofi | |
| A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors | NCT01148615 | Neoplasm Malign... | Aflibercept (AV... Docetaxel (XRP6... | 18 Years - | Sanofi | |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | NCT03845166 | Neoplasm Malign... Renal Cell Carc... Hormone Recepto... Metastatic Cast... Colorectal Canc... | XL092 Atezolizumab Avelumab | 18 Years - | Exelixis | |
| Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | NCT03491631 | Tumor, Solid Cancer, Metasta... Neoplasm Malign... | SHR9146+SHR-121... SHR9146+SHR-121... | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase 1 Safety Testing of SAR405838 | NCT01636479 | Neoplasm Malign... | SAR405838 | 18 Years - | Sanofi | |
| Longitudinal Analysis of Mental Disorders, Psychosocial Distress and Care Needs of Patients and Their Relatives | NCT04620564 | Neoplasm Malign... | 18 Years - | University of Leipzig | ||
| A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients | NCT01985191 | Neoplasm Malign... | SAR405838 Pimasertib | 18 Years - | Sanofi | |
| A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | NCT01930552 | Neoplasm Malign... | Aflibercept AVE... Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Sanofi | |
| MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) | NCT00496353 | Neoplasm | MK2461 | 18 Years - | Merck Sharp & Dohme LLC | |
| Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | NCT03324113 | Neoplasm Malign... | SAR408701 dexamethasone naphazoline diphenhydramine | 20 Years - | Sanofi | |
| A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma | NCT01943838 | Neoplasm Malign... | SAR245408 | 18 Years - | Sanofi | |
| First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | NCT04401020 | Neoplasm Malign... | SAR442257 | 18 Years - | Sanofi | |
| A Study of SAR428926 in Patients With Advanced Solid Tumors | NCT02575781 | Neoplasm Malign... | SAR428926 | 18 Years - | Sanofi | |
| A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma | NCT01943838 | Neoplasm Malign... | SAR245408 | 18 Years - | Sanofi | |
| Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance | NCT06332001 | Neoplasm Malign... | Experimental Gr... Control Group | - | European Institute of Oncology | |
| Shorter Scalp Cooling Time in Paclitaxel | NCT03266185 | Neoplasm Malign... Breast Cancer Ovarian Cancer | Shorter PICT | 18 Years - | Leiden University Medical Center | |
| Longitudinal Analysis of Mental Disorders, Psychosocial Distress and Care Needs of Patients and Their Relatives | NCT04620564 | Neoplasm Malign... | 18 Years - | University of Leipzig | ||
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | NCT05013554 | Neoplasm Malign... Breast Cancer Lung Neoplasm M... Gastric Cancer Neoplasm | SAR443216 IV SAR443216 SC | 18 Years - | Sanofi | |
| A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification | NCT02435121 | Neoplasm Malign... | SAR125844 | 18 Years - | Sanofi | |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | NCT01587040 | Neoplasm Malign... | SAR245408 SAR245409 | - | Sanofi | |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | NCT05714553 | Advanced Cancer Advanced Solid ... Neoplasm Malign... Metastatic Canc... Melanoma Classical Hodgk... Non Small Cell ... Renal Cell Carc... Urothelial Carc... Head and Neck S... Subungual Squam... Oesophageal Car... MSI-H Colorecta... Gastric Cancer Triple Negative... Endometrial Car... Pleural Mesothe... | Fosifloxuridine... Leucovorin Pembrolizumab Docetaxel | 18 Years - | NuCana plc | |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | NCT01527929 | Neoplasm Malign... | Cabazitaxel XRP... | 18 Years - | Sanofi | |
| A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer | NCT04987359 | Neoplasm Malign... | Multimodal Life... | 18 Years - | Pennington Biomedical Research Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
